Boston Scientific Corporation

we've talked about in the past with some low-cost scope competitors in Asia and Europe, which our team has really done a nice job of addressing. So we anticipate some of that headwind being mitigated as we look to 2026. So despite that, really strong performance in endo, as you know, high-margin business for us as well. Also pleased to see the enhancement and improvement in neuromodulation. The team there grew strong double digits in DBS, and the relieving acquisition has been integrated extremely well and really providing strong accretive growth to the company and a wider solution for pain physicians. And we continue, I would say, to have improved momentum in spinal cord stimulation. The team made a number of commercial changes over the past year or so, and that team is starting to come together and strengthening. So we anticipate you know, continued momentum with that neuromodulation business over the horizon. And our urology business is a fantastic franchise. It's grown a little bit under what we typically expect them to deliver. And we signal that at the end of the first quarter call, given some supply chain constraints that we're working through, that will get better in the second half of the year. And also some low-cost competition, again, that the team is addressing very proactively. The Axonics integration is a super important integration for the franchise and for the company. In the first half of the year there, we really worked through some commercial model changes, some turnover, which we anticipated, and that team is now kind of re-strengthened. We also had quite a bit of stocking that we had to work through in the first half of the year. So we anticipate improvement in the Axonics growth in the second half of the year and a very strong 2026 for Axonics. So, overall, med-surgs performed well, and hopefully that color was helpful to you.

It is. Thank you.

The next question comes from Rick Wise with CIFL. Please go ahead.